Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

No significant difference was observed in baseline serum 25-OH D3 levels between the denosumab groups (P = 0.554), confirming comparable baseline vitamin D status.

Source: Comparison of 25-OH D3 levels before and after treatment. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

A retrospective cohort study was conducted from January 2020 to December 2024, enrolling 121eligible breast cancer patients with aromatase inhibitor-associated osteoporosis from the orthopedic outpatient department of Foshan Hospital of Traditional Chinese Medicine.

Source: Abstract.

Patients were divided into two treatment groups: the alendronate group received oral alendronate sodium tablets (70 mg once weekly), while the denosumab group received subcutaneous denosumab injections (60 mg every 6 months).

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Efficacy of denosumab versus alendronate for aromatase inhibitor-associated osteoporosis in postmenopausal breast cancer patients: a retrospective analysis

Cohort study · BMC Musculoskeletal Disorders · 2025

Original publication title

Efficacy of denosumab versus alendronate for aromatase inhibitor-associated osteoporosis in postmenopausal breast cancer patients: a retrospective analysis

Yi Zhang; Wenhe Cui; Lei Hou

© The Author(s) 2025

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Both therapeutic regimens effectively improved BMD in the study population. However, comparative analysis revealed that denosumab injection (60 mg every 6 months) demonstrated significant advantages over weekly alendronate sodium (70 mg) in multiple clinical outcomes. Specifically, the denosumab group showed: (1) greater BMD improvement at all measured skeletal sites, and (2) a significantly lower incidence of VCFs (all P < 0.05) in postmenopausal women with aromatase inhibitor-associated osteoporosis.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

Bisphosphonates and denosumab can increase bone mineral density (BMD) and are used to treat osteoporosis caused by aromatase inhibitors (AIs). However, few studies have been conducted on the effects of both on vertebral compression fractures (VCFs). This article aims to compare the effects of alendronate sodium and denosumab injection on the frequency of VCFs in postmenopausal women whose osteoporosis was brought on by AIs treatment for breast cancer.

Source: Objective

Abstract: What methods does the paper describe?

A retrospective cohort study was conducted from January 2020 to December 2024, enrolling 121eligible breast cancer patients with aromatase inhibitor-associated osteoporosis from the orthopedic outpatient department of Foshan Hospital of Traditional Chinese Medicine. Patients were divided into two treatment groups: the alendronate group received oral alendronate sodium tablets (70 mg once weekly), while the denosumab group received subcutaneous denosumab injections (60 mg every 6 months). Both groups were supplemented with calcitriol and calcium carbonate/vitamin D3 tablets as baseline therapy. The observation period was 12 months.

The following parameters were compared between the two groups before and after treatment: BMD, 25-hydroxy Vitamin D3 (25-OH D3), β-C-terminal telopeptide of type I collagen (β-CTX) and Procollagen I N-Terminal Propeptide (PINP), Visual Analog Scale (VAS) scores and Incidence of VCFs. Statistical analysis was performed using SPSS 27.0.

Source: Methods

Abstract: Results

The study included a total of 121 patients. Post-treatment analysis revealed a significantly higher overall response rate in the denosumab group(n = 57) (91.22%) compared to the alendronate group(n = 64) (82.81%; P < 0.05). Notably, the denosumab group demonstrated superior outcomes in the following two areas: (1) significantly greater improvement in BMD, (2) lower incidence of vertebral compression fractures (both P < 0.05). Both treatment groups showed statistically significant improvements in bone metabolism markers following treatment (P < 0.01).

Source: Results

Abstract: Conclusion

Both therapeutic regimens effectively improved BMD in the study population. However, comparative analysis revealed that denosumab injection (60 mg every 6 months) demonstrated significant advantages over weekly alendronate sodium (70 mg) in multiple clinical outcomes. Specifically, the denosumab group showed: (1) greater BMD improvement at all measured skeletal sites, and (2) a significantly lower incidence of VCFs (all P < 0.05) in postmenopausal women with aromatase inhibitor-associated osteoporosis.

Source: Conclusion
Authors’ abstract

Objective

Bisphosphonates and denosumab can increase bone mineral density (BMD) and are used to treat osteoporosis caused by aromatase inhibitors (AIs). However, few studies have been conducted on the effects of both on vertebral compression fractures (VCFs). This article aims to compare the effects of alendronate sodium and denosumab injection on the frequency of VCFs in postmenopausal women whose osteoporosis was brought on by AIs treatment for breast cancer.

Methods

A retrospective cohort study was conducted from January 2020 to December 2024, enrolling 121eligible breast cancer patients with aromatase inhibitor-associated osteoporosis from the orthopedic outpatient department of Foshan Hospital of Traditional Chinese Medicine. Patients were divided into two treatment groups: the alendronate group received oral alendronate sodium tablets (70 mg once weekly), while the denosumab group received subcutaneous denosumab injections (60 mg every 6 months). Both groups were supplemented with calcitriol and calcium carbonate/vitamin D3 tablets as baseline therapy. The observation period was 12 months.

The following parameters were compared between the two groups before and after treatment: BMD, 25-hydroxy Vitamin D3 (25-OH D3), β-C-terminal telopeptide of type I collagen (β-CTX) and Procollagen I N-Terminal Propeptide (PINP), Visual Analog Scale (VAS) scores and Incidence of VCFs. Statistical analysis was performed using SPSS 27.0.

Results

The study included a total of 121 patients. Post-treatment analysis revealed a significantly higher overall response rate in the denosumab group(n = 57) (91.22%) compared to the alendronate group(n = 64) (82.81%; P < 0.05). Notably, the denosumab group demonstrated superior outcomes in the following two areas: (1) significantly greater improvement in BMD, (2) lower incidence of vertebral compression fractures (both P < 0.05). Both treatment groups showed statistically significant improvements in bone metabolism markers following treatment (P < 0.01).

Conclusion

Both therapeutic regimens effectively improved BMD in the study population. However, comparative analysis revealed that denosumab injection (60 mg every 6 months) demonstrated significant advantages over weekly alendronate sodium (70 mg) in multiple clinical outcomes. Specifically, the denosumab group showed: (1) greater BMD improvement at all measured skeletal sites, and (2) a significantly lower incidence of VCFs (all P < 0.05) in postmenopausal women with aromatase inhibitor-associated osteoporosis.

Publication and source details

Original title: Efficacy of denosumab versus alendronate for aromatase inhibitor-associated osteoporosis in postmenopausal breast cancer patients: a retrospective analysis

Yi Zhang; Wenhe Cui; Lei Hou

BMC Musculoskeletal Disorders · 2025

© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T00:50:09.707530+00:00

DOI: 10.1186/s12891-025-09280-w · PMC12613706